The Polyclonal Antibody Market, estimated at USD 1,230.2 Mn in 2025, is expected to exhibit a CAGR of 5.9% and reach USD 1,837.6 Mn by 2032.
The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.
Increasing research and development activities by key market players is expected to drive the global polyclonal antibody market growth over the forecast period. For instance, in April 2021, SAB Biotherapeutics, Inc., a pharmaceutical company, conducted a Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2. The trial, ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health.
Global Polyclonal Antibody Market - Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and consequent lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The pandemic hampered the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. The private healthcare is one such sector that was significantly impacted by the COVID-19 pandemic.
Many patients suffering from COVID-19 had a severe respiratory infection that required hospitalization and mechanical ventilation. Governments of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures in the countries. Moreover, the governments of various countries have collaborated with universities around the globe to find novel treatments option for COVID-19 and its related complications. However, the COVID-19 pandemic had a negative impact on the global polyclonal antibody market. For instance, in November 2022, according to the data published by National Center for Biotechnology Information, monoclonal and polyclonal antibodies have many advantages as these reduce viral levels and the resulting damage to the lungs. Monoclonal and polyclonal antibodies enhanced symptoms in non-hospitalised covid-19 patients and allowed non-hospitalised patients to heal more rapidly. This treatment is only carried out in people who did not have immunoglobulins to SARS-CoV-2; it has also worked better on individuals/cases with higher virus levels.